Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Lumber Liquidators Raised to Buy at Janney
50:13 - March 3 -- Bloomberg’s Scarlet Fu reports on the latest market news and analyst calls on “Market Makers.”
  • Fiat, Ford, GM All Miss Sales Estimates
  • Boehner Will Hold Homeland Security Funding Vote
  • Inside Retail’s CEO Revolving Doors and Shakeups